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patient had a diagnosis of HIV infection and AIDS atKaposi’s sarcoma (KS) was first described in 1872 by Mortiz
Kaposi. Before the introduction of combination antiretroviral
therapy (cART) in 1996, HIV-infected individuals had
a 20,000-fold higher risk of developing KS compared to HIV-
uninfected individuals.1 Men who have sex with men are at
a significantly higher risk compared to patients who acquired
HIV via other routes.1 After the introduction of cART, the
standardized incidence rate of KS has decreased from 2628.5
per 100,000 person-years in 1992e1995 to 356.3 per 100,000
person-years in 2000e2003 in the United States.2 In a survey
conducted at a major hospital for HIV care in Taiwan, the
crude incidence of KS has decreased from 20.3% to 2.7% after
the introduction of cART in 1997.3 However, KS remains the
most common HIV-associated malignancy in the cART era.2,4
Skin manifestations such as pink to purple patches or
plaques are the most common presentations of KS,5
followed by visceral involvement that occurs in more than
25% of cases.6 Of visceral KS, KS of the gastrointestinal
tract is most frequently seen, followed by pulmonary KS.5
The pathogenesis of KS in HIV-infected patients involves
the interactions between human herpes virus 8 (HHV-8),
HIV infection, cytokines, and angiogenic factors.7e9 The
decrease in the incidence of KS can be explained by the
sustained suppression of HIV replication by cART with
resultant immune reconstitution, the decrease of its
angiogenic Tat protein, and the reduction of cytokines that
trigger the production of angiogenic factors.10
With the widespread use of cART, immune reconstitution
inflammatory syndrome (IRIS) associated with KS (KS-IRIS) is
increasingly reported in HIV-infected patients.11e15 In this
report, we describe a case of clinically deteriorating KS of
the lungs and skin at 3.5 months after cART despite an
increase of CD4 lymphocyte counts. KS regressed success-
fully with continuation of chemotherapy and cART.
Case report
A 50-year-old homosexual male with HIV infection sought
medical attention at our hospital due to rapidly progressive,Figure 1. (A) Chest radiography at the time of HIV diagnosis show
radiography after four courses of chemotherapy and 2.5 months of c
up chest radiography at the time of deteriorating cutaneous lesio
sarcoma.painful ecchymosis at the right thigh for 2 weeks. The
a hospital 5 months before this evaluation, when he pre-
sented with multiple, purplish maculo-papular rashes and
nodules that involved the face and trunk. The lesions
gradually involved the skin of the four limbs and oral cavity,
and he experienced a weight loss of 20 kg in 5 months. A
chest radiograph revealed multiple fluffy nodular infiltrates
at the bilateral lung fields (Fig. 1A). His baseline CD4 count
was 46 cells/mL and plasma HIV-1 RNA load was
93,000 copies/ml. A diagnosis of KS of the skin, oral cavity,
and lungs was made. He began to receive cART with efa-
virenz, lamivudine, and abacavir, and chemotherapy (lipo-
somal doxorubicin, 30 mg, administered every 3 weeks).
CD4 count increased to 119 cells/mL 2 months after cART,
and KS of the lungs and skin regressed after four courses of
chemotherapy (Fig. 1B), and he started to gain weight after
cART was initiated.
Six weeks before admission, he began to notice an ill-
defined purplish and hard ecchymosis at the right thigh
that developed insidiously in the beginning and rapidly
progressed to involve the right knee joint, which resulted
in pain despite the use of analgesics (Fig. 2). He denied
a history of trauma to this region. Follow-up CD4 count
and plasma HIV-1 RNA load was 154 cells/mL and
<40 copies/mL, respectively. Computed tomography of
the lower limbs disclosed hematoma and subcutaneous
tissue swelling at the right medial thigh. Pain improved
initially with acetaminophen treatment, but ecchymosis
worsened in association with thrombocytopenia and
rapidly increasing infiltrates of the bilateral lungs in chest
radiography (Fig. 1C). He also had several episodes of
hemoptysis and fever that resulted in exertional dyspnea
and hypoxia.
Upon examination, he appeared acutely ill. He was
afebrile with a temperature of 36.7C, pulse rate of 109
beats/minute, blood pressure of 121/68 mmHg, and respi-
ratory rate of 22 breaths/minute. Several purplish nodules
were noted at the upper palates without oral candidiasis.
The chest wall expanded symmetrically with bibasilar
crackles. An ecchymosis of ill-defined border extended
from the right medial thigh to the right posterior knee,ing several nodular infiltrates in both lungs. (B) Follow-up chest
ART showing significant regression of KS of the lung. (C) Follow-
n. cART Z combination antiretroviral therapy; KS Z Kaposi’s
Figure 2. Newly developed Kaposi’s sarcoma at the inguinal
region and inner thigh.
IRIS of Kaposi’s sarcoma 311which caused pain on extension of the knee joint. Several
enlarged, movable lymph nodes were noted at the bilateral
submandibular and right peri-auricular regions. White blood
cell count was 4540/mL, hemoglobin 11.8 g/dL, and platelet
count 110,000/mL.
A thoracentesis yielded bloody pleural effusion (total
red blood cell count, 210,000 cells/ml; neutrophil count,
500 cells/ml with 74% lymphocytes), and HHV-8 DNA was
detectable in a pleural effusion specimen using real-time
polymerase chain reaction assay.16 The bronchoscopy
revealed no endobronchial lesion or active bleeder, but the
pathology of transbronchial lung biopsy and sonography-
guided lung biopsy specimens showed spindle cells with
occasional slit-like spaces adjacent to the unremarkable
alveolar tissues. Immunohistochemically, these biopsied
tissues were positive for CD31 and HHV-8, which was
consistent with KS. Further courses of chemotherapy
(liposomal doxorubicin, 35 mg per course) were adminis-
tered, and hemoptysis ceased; the right leg pain and
hematoma gradually improved, while the follow-up platelet
count increased to 120,000/mL. Follow-up chest radiog-
raphy 15 days after three courses of chemotherapy showed
a significant regression of the bilateral lung infiltrates. The
serial CD4 counts, plasma viral loads, and HHV-8 viral loads
are shown in Fig. 3.0
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Figure 3. Changes in CD4 count and plasma HHV-8 viral
load at baseline and 2 and 4 months after cART. cART Z
combination antiretroviral therapy; HHV-8 Z human herpes
virus 8.Discussion
In the era of cART, cases of KS-IRIS are increasingly re-
ported, and the incidence rate ranges from 6% to 12%
among HIV-infected patients who initiate cART.17e19 A
prospective study conducted in Mozambique identified the
predictors of KS-IRIS in the cART era, which included
pretreatment KS, high plasma HIV RNA load, detectable
plasma HHV-8 DNA before cART, and a hemotocrit <30%.18
The risk may reach its peak during the first 2 months of
cART.11 All four risk factors for KS-IRIS are present in our
patient, who had a rapid increase of CD4 count 2.5 months
after cART. The immune reconstitution following cART
caused KS-IRIS.
Previous studies have shown that HHV-8 DNA levels
decreased and the anti-HHV-8 antibody titers increased in
patients who developed KS-IRIS.12,18 However, our patient
had an initial decline of the HHV-8 viral load with chemo-
therapy and cART, followed by an increase of the HHV-8
viral load when KS-IRIS was detected. The temporal rela-
tionship between the increase of his CD4 count and rapid
worsening of KS at 3.5 months after cART is consistent with
the diagnosis of KS-IRIS.
The appropriate management of IRIS-KS remains unclear
because the number of such cases is small. A review of the
literature suggests that chemotherapy will cause successful
regression of pulmonary KS.11 Therefore, continuation of
cART and reinstitution of chemotherapy with liposomal
doxorubicin should be considered, especially in patients
with visceral involvement.12
In conclusion, KS-IRIS should be considered in HIV-
infected patients with pre-existing KS who had clinical
worsening of dermatologic and pulmonary lesions after
initiation of cART.References
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